新型冠状病毒肺炎与糖尿病相互作用中的心脏代谢改变：现有知识和未来方向。
Cardiometabolic Alterations in the Interplay of COVID-19 and Diabetes: Current Knowledge and Future Avenues.
机构信息
Department of Medicine, University of Central Florida College of Medicine, Orlando, FL 32827, USA.
Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of South Carolina, Columbia, SC 29208, USA.
出版信息
Int J Mol Sci. 2021 Nov 15;22(22):12311. doi: 10.3390/ijms222212311.
Abstract
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease 2019 [COVID-19]) pandemic has raged for almost two years, with few signs of a sustained abatement or remission [...].
摘要
严重急性呼吸综合征冠状病毒 2 (SARS-CoV-2)（2019 年冠状病毒病[COVID-19]）大流行已经肆虐了近两年，几乎没有持续缓解或消退的迹象[... ]。
相似文献
1
Cardiometabolic Alterations in the Interplay of COVID-19 and Diabetes: Current Knowledge and Future Avenues.新型冠状病毒肺炎与糖尿病相互作用中的心脏代谢改变：现有知识和未来方向。
Int J Mol Sci. 2021 Nov 15;22(22):12311. doi: 10.3390/ijms222212311.
2
Urgent Need for Studies of the Late Effects of SARS-CoV-2 on the Cardiovascular System.迫切需要对SARS-CoV-2对心血管系统的晚期影响进行研究。
Circulation. 2021 Mar 30;143(13):1271-1273. doi: 10.1161/CIRCULATIONAHA.120.051362. Epub 2020 Sep 24.
3
COVID-19 and cardiovascular diseases.新型冠状病毒肺炎与心血管疾病。
J Mol Cell Biol. 2021 Jul 6;13(3):161-167. doi: 10.1093/jmcb/mjaa064.
4
Evidence of Severe Acute Respiratory Syndrome Coronavirus 2 Replication and Tropism in the Lungs, Airways, and Vascular Endothelium of Patients With Fatal Coronavirus Disease 2019: An Autopsy Case Series.严重急性呼吸综合征冠状病毒 2 在 COVID-19 死亡患者肺部、气道和血管内皮中的复制和嗜性的证据：一项尸检病例系列研究。
J Infect Dis. 2021 Mar 3;223(5):752-764. doi: 10.1093/infdis/jiab039.
5
The cardiovascular disorders and prognostic cardiac biomarkers in COVID-19.COVID-19 中的心血管疾病与预后性心生物标志物。
Mol Biol Rep. 2021 Feb;48(2):1763-1771. doi: 10.1007/s11033-021-06148-9. Epub 2021 Jan 22.
6
Therapeutic uncertainties in people with cardiometabolic diseases and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 or COVID-19).患有心血管代谢疾病和严重急性呼吸综合征冠状病毒 2（SARS-CoV-2 或 COVID-19）的患者的治疗不确定性。
Diabetes Obes Metab. 2020 Oct;22(10):1942-1945. doi: 10.1111/dom.14062. Epub 2020 May 19.
7
Impaired glucose regulation, SARS-CoV-2 infections and adverse COVID-19 outcomes.葡萄糖调节受损、严重急性呼吸综合征冠状病毒 2 感染与不良的 COVID-19 结局。
Transl Res. 2022 Mar;241:52-69. doi: 10.1016/j.trsl.2021.11.002. Epub 2021 Nov 9.
8
Viral Infection and Cardiovascular Disease: Implications for the Molecular Basis of COVID-19 Pathogenesis.病毒感染与心血管疾病：对 COVID-19 发病机制分子基础的影响。
Int J Mol Sci. 2021 Feb 7;22(4):1659. doi: 10.3390/ijms22041659.
9
A novel coronavirus meets the cardiovascular system: Society for Cardiovascular Pathology Symposium 2021.一种新型冠状病毒与心血管系统的相遇：2021年心血管病理学会研讨会
Cardiovasc Pathol. 2021 Jul-Aug;53:107336. doi: 10.1016/j.carpath.2021.107336. Epub 2021 Apr 23.
10
Diabetes, obesity and COVID-19: A complex interplay.糖尿病、肥胖与 COVID-19：复杂的相互作用。
Diabetes Obes Metab. 2020 Oct;22(10):1892-1896. doi: 10.1111/dom.14134. Epub 2020 Jul 28.
引用本文的文献
1
The Importance of a Novel Syndemic Approach for Cardiometabolic Diseases.一种针对心脏代谢疾病的新型综合征方法的重要性。
Curr Med Chem. 2024;31(18):2483-2485. doi: 10.2174/0929867331666230918114009.
2
Associations between Periodontitis, COVID-19, and Cardiometabolic Complications: Molecular Mechanisms and Clinical Evidence.牙周炎、新冠病毒病与心血管代谢并发症之间的关联：分子机制与临床证据
Metabolites. 2022 Dec 26;13(1):40. doi: 10.3390/metabo13010040.
3
The Dual Pandemics of COVID-19 and Obesity: Bidirectional Impact.新冠疫情与肥胖症双重大流行：双向影响
Diabetes Ther. 2022 Oct;13(10):1723-1736. doi: 10.1007/s13300-022-01311-2. Epub 2022 Aug 27.
4
The Role of Physicians' Digital Tools in Pharmacological Management of Type 2 Diabetes Mellitus.医生数字工具在 2 型糖尿病药物管理中的作用。
Medicina (Kaunas). 2022 Aug 6;58(8):1061. doi: 10.3390/medicina58081061.
5
Cholesterol Metabolic Markers for Differential Evaluation of Patients with Hyperlipidemia and Familial Hypercholesterolemia.胆固醇代谢标志物用于鉴别高脂血症和家族性高胆固醇血症患者。
Dis Markers. 2022 Apr 21;2022:2008556. doi: 10.1155/2022/2008556. eCollection 2022.
6
Metformin: Sex/Gender Differences in Its Uses and Effects-Narrative Review.二甲双胍：用途和效果的性别差异——叙述性综述。
Medicina (Kaunas). 2022 Mar 16;58(3):430. doi: 10.3390/medicina58030430.
本文引用的文献
1
COVID-19 and metabolic disease: mechanisms and clinical management.新型冠状病毒肺炎与代谢性疾病：机制与临床管理。
Lancet Diabetes Endocrinol. 2021 Nov;9(11):786-798. doi: 10.1016/S2213-8587(21)00244-8. Epub 2021 Oct 4.
2
COVID-19 and Obesity: Role of Ectopic Visceral and Epicardial Adipose Tissues in Myocardial Injury.新型冠状病毒肺炎和肥胖：异位内脏和心外膜脂肪组织在心肌损伤中的作用。
Front Endocrinol (Lausanne). 2021 Aug 16;12:726967. doi: 10.3389/fendo.2021.726967. eCollection 2021.
3
The role of GLP-1 receptor agonists during COVID-19 pandemia: a hypothetical molecular mechanism.胰高血糖素样肽-1受体激动剂在新冠疫情期间的作用：一种假设的分子机制。
Expert Opin Drug Saf. 2021 Nov;20(11):1309-1315. doi: 10.1080/14740338.2021.1970744. Epub 2021 Aug 25.
4
COVID-19 and the kidney: time to take a closer look.COVID-19 与肾脏：是时候进一步观察了。
Int Urol Nephrol. 2022 May;54(5):1053-1057. doi: 10.1007/s11255-021-02976-7. Epub 2021 Aug 12.
5
The evolving story of incretins (GIP and GLP-1) in metabolic and cardiovascular disease: A pathophysiological update.肠促胰岛素（GIP和GLP-1）在代谢性疾病和心血管疾病中的演变历程：病理生理学最新进展
Diabetes Obes Metab. 2021 Sep;23 Suppl 3:5-29. doi: 10.1111/dom.14496.
6
Obesity-Related Inflammation and Endothelial Dysfunction in COVID-19: Impact on Disease Severity.新冠病毒肺炎中肥胖相关炎症与内皮功能障碍：对疾病严重程度的影响
J Inflamm Res. 2021 May 27;14:2267-2276. doi: 10.2147/JIR.S282710. eCollection 2021.
7
Low HDL and high triglycerides predict COVID-19 severity.低 HDL 胆固醇和高甘油三酯与 COVID-19 严重程度相关。
Sci Rep. 2021 Mar 30;11(1):7217. doi: 10.1038/s41598-021-86747-5.
8
Diabetes, obesity, and insulin resistance in COVID-19: molecular interrelationship and therapeutic implications.2019冠状病毒病中的糖尿病、肥胖与胰岛素抵抗：分子相互关系及治疗意义
Diabetol Metab Syndr. 2021 Mar 1;13(1):23. doi: 10.1186/s13098-021-00639-2.
9
Impact of COVID-19 pandemic and diabetes on mechanical reperfusion in patients with STEMI: insights from the ISACS STEMI COVID 19 Registry.COVID-19 大流行和糖尿病对 STEMI 患者机械再灌注的影响：来自 ISACS STEMI COVID 19 登记处的见解。
Cardiovasc Diabetol. 2020 Dec 18;19(1):215. doi: 10.1186/s12933-020-01196-0.
10
Metabolic risk factors and risk of Covid-19: A systematic review and meta-analysis.代谢风险因素与 COVID-19 风险：系统评价和荟萃分析。
PLoS One. 2020 Dec 15;15(12):e0243600. doi: 10.1371/journal.pone.0243600. eCollection 2020.
Zotero 插件